Cantor Fitzgerald raised the firm’s price target on Teladoc (TDOC) to $11 from $10 and keeps an Overweight rating on the shares. The firm expects the stock will see some relief following the soft 2025 guidance, saying in a research note that the overhang on the stock was largely due to the lack of investor confidence and management commentary in the direction of both the Integrated Care and BetterHelp segments. Cantor says the 2025 guidance is encouraging to weak sentiment.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TDOC:
- Teladoc price target lowered to $8 from $9 at TD Cowen
- Teladoc price target raised to $12 from $10 at Barclays
- Teladoc Health Reports Q3 2024 Financial Results
- Closing Bell Movers: Microsoft, Meta both down about 3% despite earnings beats
- Teladoc sees FY24 revenue growth % low single digits to mid-single digits y/y